Načítá se...

Would Tirofiban Have Been Shown Non-Inferior to Abciximab Had the TENACITY Trial Not Been Terminated for Financial Reasons?

OBJECTIVES: To investigate whether tirofiban would have been non-inferior to abciximab had the trial completed enrollment, and we place the termination of this trial in a broader research ethics context. BACKGROUND: TENACITY was terminated by the sponsor for financial reasons. At the time, event rat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Berger, Peter B., Williams, Judson B., Hasselblad, Vic, Chiswell, Karen, Pieper, Karen S., Califf, Robert M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4156852/
https://ncbi.nlm.nih.gov/pubmed/23379785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1540-8183.2013.12020.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!